June 26, 2023 4:38pm
Time to enter the fray and rescue wounded equities, there’s money to be made
Pre-open Indications: 1 Hit and 2 Miss
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Never leave an investor uninformed! Framing the main takeaway … pricing, volume and machine trading creates volatility and liquidity!
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed DOWN -12.72 points (-0.04%), the S&P closed DOWN -19.51 points (-0.45%) while the Nasdaq closed DOWN -156.74 points (-1.16%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes dived as the Nasdaq slumped about 1% on Monday as investors experienced the final trading week of June.
Monday (6/26) … RegMed Investors’ (RMi) pre-open: “tip-toe into the sector in Q and June’s final week. A few wounded equities offer signs that the pullback could be slowing.” … https://www.regmedinvestors.com/articles/13018
Pre-open Indications: 1 Hit < Vericel (VCEL +$0.02)> and 2 Miss <Mesoblast (MESO -$0.19), Intellia Therapeutics (NTLA +$0.90)>
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …
- Monday’s advance/decline line opened negative at 8 up/ 26 down and 1 flat, stayed negative with 7 up/ 26 down and 2 flats at the mid-day, ending with a negative close of 8/26 and 1 flat
- Friday’s advance/decline line opened negative at 5 up/ 29 down and 1 flat, stayed negative with 5 up/ 30 down and 0 flat at the mid-day, ending with a negative close of 9 incliners, 26 decliners and 0 flat
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB was down -1.11% and the XBI was down -2.42%
- Friday, the IBB was down -1.04% and the XBI was down -1.70%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was up +0.76 point or +5.65% at 14.20
- Friday was up +0.53. point or +4.11% at 13.44
Closing Down (10 of 26):
- Sage Therapeutics (SAGE -$1.83 after Friday’s -$4.84),
- Ultragenyx (RARE -$1.58 after Friday’s -$1.35),
- Alnylam Pharmaceuticals (ALNY -$1.34 after Friday’s -$6.38),
- Blueprint Medicine (BLMC -$1.10 after Friday’s -$0.26)
- Ionis Pharmaceuticals (IONS -$0.54 after Friday’s -$1.56),
- Regenxbio (RGNX -$0.48),
- Verve Therapeutics (-$0.45),
- Prime Medicine (PRME -$0.36 after Friday’s +$0.04),
- BioLife Solutions (BLFS -$0.31 after Friday’s -$0.43),
- Caribou Biosciences (CRBU -$0.25 after Friday’s +$0.07),
Flat (1):
- Biostage (OTCQB: BSTG)
Closing Up (8 of 8):
- Intellia Therapeutics (NTLA +$0.90 after Friday’s -$1.00),
- CRISPR Therapeutics (CRSP +$0.20 after Friday’s -$0.91),
- Beam Therapeutics (BEAM +$0.16 after Friday’s -$0.72),
- Adverum Biotechnologies (ADVM +$0.08),
- Compass Therapeutics (CMPX +$0.03),
- Vericel (VCEL +$0.02 after Friday’s +$0.65),
- uniQure NV (QURE +$0.02 after Friday’s +$0.31),
- Homology Medicine (FIXX +$0.0089)
Q2/23 – June
- Monday closed negative with 8 incliners, 26 decliners and 1 flat
- Last Friday closed negative with 9 incliners, 26 decliners and 0 flat
The BOTTOM LINE: I try to keep it simple … and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
A losing session follows a losing week.
After stabs to the heart of share pricing – some deserved; examine the execution of electronic and algorithmic trading … looking for gains after newest bottoms!
The only issue is the end of Q2 next week; yet, Q reporting is weeks if not a month away.
Investors should be considering pre-emptive moves after four (4) down slides of the sector.
Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
Reiterating, there is VALUE out there even as electronic trading and algorithms take their toll on share pricing however, it’s about playing or betting and timing of the sector.
Unresolved issues --- political investigation of the White House and the Bidens, escalation of the Ukraine war, a Russia uncertainty after a on mercenary versus Russia fight and the major issue - recession - US and global could freezing investors' mood.
Last week, U.S. stocks sputtered after a recent rally, with the Nasdaq snapping its eight-week winning streak after Fed Chair Powell signaled there could be more interest rate hikes ahead.
The top three (3) performing in the session:
· Monday: Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)
· Friday: Vericel (VCEL) – again, uniQure NV (QURE) and Generation BIO (GBIO)
While The worst three (3) in the session:
· Monday: Sage Therapeutics (SAGE), Ultragenyx (RARE) and Alnylam Pharmaceuticals (ALNY) - again
· Friday: Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE) and Ionis Pharmaceuticals (IONS)
WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.
I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.
The NO spin zone! U.S. public shareholders deserve accountability …
Biostage (OTCQB: BSTG) … so many issues from the past as many of those “miscreant management” members are still employed!
Monday closed flat with 0 shares traded after Friday closed down -$0.19 with 2,673 shares traded, Thursday closed down -$0.40 with 5,400, Wednesday closed down -$0.12 with 2,676 shares traded, Tuesday closed down -$0.08 with 1,523 shares traded and Monday’s market holiday post <3-month average = 916 shares>
· Biostage (OTCQB: BSTG) finally announced a clinical trial initiation for an IND that was approved on 3/20/2020 – what’s with the time (3 years and 2 months) interval?
· Question: Review the number of shares traded on a weekly and monthly basis … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?
· Accumulated deficit: $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!
· OTCQB: BSTG is holding their annual meeting on 7/19, to vote the Beijing, China designated directors …??? Certainly NOT a US company ANYMORE!
My question that resounds, that should be asked is how many companies are at the end of sentiments … leash?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
